We describe a novel biogenesis factor of the 90S pre-ribosome, Puf-A, which is a negative transcriptional target of p53. The expression of Puf-A is not only upregulated in advanced human lung cancer and tumors of patients especially with TP53 mutation, but also is highly prognostic for stage I lung cancer. Loss of Puf-A expression prevents 
Introduction
Oncogenic Kras activates both the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways and subsequently enhances c-Myc expression, which is involved in cancer initiation and/or maintenance (McCubrey, Steelman et al., 2012) . Mice with KRAS and TP53 dual mutations produce phenotypically more advanced and faster growing lung tumors that are more resistant to chemotherapy compared to mice with KRAS mutation alone (Chen, Cheng et al., 2012 , Oliver, Mercer et al., 2010 . Clinically, both KRAS and TP53 mutations in patients with lung cancer are important prognostic markers for shortened survival and have been associated with significantly worse outcomes for cytotoxic chemotherapy than observed with wild-type genotypes (Graziano, Gu et al., 2010 , Tsao, Aviel-Ronen et al., 2007 .
Enhancement of ribosome biogenesis activity is crucial for cell proliferation, transformation and consequent tumorigenesis through activation of RAS and MYC or inactivation of TP53 (Truitt & Ruggero, 2016) . During early ribosome biogenesis in the nucleolus, the long pre-rRNA is assembled with about 70 ribosome biogenesis factors and several small nucleolar RNAs (snoRNAs) to form a large 90S pre-ribosome, which is a critical precursor of 40S, 60S and 80S ribosomes (Oeffinger, 2016) . Recently, the architecture of 90S pre-ribosome in yeast was unveiled and further revealed how the prerRNA folding, processing, and assembly at the first stage of ribosome biogenesis (Chaker-Margot, Barandun et al., 2017 , Kornprobst, Turk et al., 2016 , Sun, Zhu et al., 2017 . Although many studies have shown various factors to be crucial for 90S assembly in yeast (Kressler, Hurt et al., 2017) , it remains unclear which are the key factors involved in maintaining the integrity of 90S in mammalian cells. Therefore, unraveling the detailed machinery of 90S ribosome assembly could steer new therapeutic directions for KRAS-and/or TP53-mutated cancers.
Through comparative evolutionary genomic analysis, we first identified a novel protein, Puf-A (also known as KIAA0020 or PUM3), which belongs to a Puf-family of RNA-binding proteins highly expressed in primordial germ cells (Kuo, Wang et al., 2009 ). Puf-A plays an important role in the formation and specification of germ cell lineage, as knockdown of Puf-A specifically resulted in abnormal migration of primordial germ cells (Kuo et al., 2009 ). However, the pathophysiologic roles of Puf-A in cancer cells are largely unknown. The present study was undertaken to further identify the molecular machinery for regulation of Puf-A expression and determine its critical roles in ribosome biogenesis and cancer progression in order to provide both a diagnostic marker and a therapeutic target for combating TP53-mutated cancers.
Results

Puf-A is upregulated in advanced human lung cancer and tumors with TP53 mutation
The expression of Puf-A protein and RNA in human lung adenocarcinomas (ADCs) and squamous cell carcinomas (SCCs) was first examined and found to be elevated compared to non-neoplastic lung samples (Fig. 1A and Fig. S1a, left panel) . According to a histological scoring system, H-score (Table S1 ), the expression of Puf-A was increased significantly in high grade tumors compared to low grade (Fig. 1A) . Furthermore, grade 3 tumor cells exhibited not only greater Puf-A expression in nucleoli but also in the nucleoplasm (Fig. 1A ) compared to grade 1 or 2 tumor cells. Also, PUF-A RNA was significantly increased in higher grade and advanced stage tumors (Fig. S1a , middle and right panels). The Kaplan-Meier analysis of public datasets revealed that increased PUF-A RNA expression correlated with shortened overall survival as well as progression-free survival of patients with lung cancer (Fig. 1B, left panel and Fig. S1b) . Notably, the expression of Puf-A is highly prognostic for stage I lung cancer in our study. While the 5-years overall survival of stage I patients is 67.8%, consistent with the reported 50-70% (Der, Zhu et al., 2015) , those with high and low Puf-A expression was 57.0% and 85.7%, (p = 0.038) respectively (Fig. 1B , right panel and Table S2 ). If confirmed in a larger study, Puf-A may be an important novel prognostic marker for stage I lung cancer.
It should be noted that PUF-A was significantly increased in tumor cells of patients with mutated TP53 mutation (Fig. S1c ) compared to tumors with wild-type genotypes. To assess whether the status of TP53 correlates with Puf-A expression, tissue sections from patients with lung cancer were further evaluated for the expression of p53 by immunohistochemical analysis ( Fig. 1C and Table S1 ). Strong p53 nuclear staining was detected in 31 (37.8%) tumor samples from patients with lung cancer (Fig. 1C , left panel; p53 mut), suggesting that these tumors frequently harbored mutated TP53 (Xie, Lan et al., 2014) . Other samples with weak or no staining of p53 conceivably had wild-type p53 which has a short half-life (Fig. 1C , left panel; p53 WT). Interestingly, the percentage of samples with high p53 expression in these patients was correlated with tumor grade (Fig.   1C , middle panel). Moreover, H-score analysis showed that Puf-A expression was significantly increased in tumors with high p53 expression, compared to those with low p53 (Fig. 1C, right panel) , suggesting that p53 could regulate Puf-A expression.
In p53
+/+ -H460 (lung cancer) and -HCT116 (colon cancer) cells after silencing of p53 expression, the expression of Puf-A protein and RNA was significantly increased (Fig. S1d) , consistent with findings of higher Puf-A expression in p53
-/--as compared to p53 +/+ -HCT116 cells (Fig. 1D) . In contrast, exogenous p53 significantly suppressed the promoter activity of PUF-A in both p53 +/+ -and p53
-/--HCT116 cells (Fig. 1E, left panel) .
Similarly, in p53
-/--H1299 (lung cancer) cells, exogenous p53 not only reduced the promoter activity of PUF-A (Fig. 1E , right panel) but also Puf-A protein and RNA expression in a dose-dependent manner compared to control cells (Fig. 1F) . Furthermore, the chromatin immunoprecipitation (ChIP) assay revealed that p53 binds directly to the p53RE-1 and -2 sites of PUF-A locus in H1299 cells after transduction with exogenous p53 or in p53 +/+ -HCT116 cells (Fig. 1G ). These results indicate that p53 transcriptionally suppresses Puf-A expression.
Puf-A is transcriptionally regulated by oncogenic Kras G12D and c-Myc
Oncogenic Kras signaling was reported to be associated with c-Myc expression in cancer (DeNicola, Karreth et al., 2011) . The Puf-A expression at the RNA level was significantly increased in tumors of patients with mutated KRAS and high MYC expression compared to tumors with wild-type genotypes (Fig. S1e) . In H1299 cells after transduction with Kras G12D or c-Myc, the expression levels of Puf-A protein and RNA were increased, respectively, compared to control cells ( Fig. 2A and 2B ). Furthermore, both Kras G12D and c-Myc increased PUF-A promoter activity by 2.2-and 3.2-fold ( 
Silencing of Puf-A inhibits Kras G12D /p53
-/-
-induced tumor progression in lungs
We previously established an inducible lung ADC model in CCSP-rtTA/ TetOCre/LSL-Kras G12D /p53 +/+ mice ( Fig. 2E ) that gave rise to adenoma and ADC in the lungs after Kras G12D induction for 6 and 12 weeks, respectively (Cho, Lai et al., 2011) . It was found that the Puf-A-positive cells were further increased in bronchiolar ADC of the lungs, while there were only a few Puf-A-positive cells scattered within the alveolar tumor region. Mutation of KRAS and TP53 genes often occurs concurrently and with similar frequencies in human lung cancer (Yamaguchi, Kugawa et al., 2012) . The progression from adenoma to ADC in mutant KRAS-driven mouse models can be accelerated through loss of the TP53 tumor-suppressor gene (Jackson, Olive et al., 2005) .
In CCSP-rtTA/TetO-Cre/LSL-Kras G12D /p53 flox/flox mice, the first appearance of adenomas in the lung occurred at 2 weeks, and the progression from adenoma to ADC was accelerated at 8 weeks after Kras G12D activation and p53 deletion (Fig. 2F ). (Fig. 1C ).
Two ADC cell lines (KP-1 and KP-2) derived from Kras G12D /p53
ADCs were used for selection of shRNAs for Puf-A silencing (Fig. 2G ). After transduction with shPuf-A-1 and -2, the expressions of Puf-A decreased significantly in both lines of cells (Fig. 2G ) compared with control cells. We further determined whether a reduction in Puf-A expression after the onset of adenomas might prevent progression to ADCs in the lungs. As shown in Figure 2D , the lentiviral vectors expressing shPuf-A-1, shPuf-A-2 or control shLacZ were delivered intranasally four times between weeks 2 and 4 to the lungs of CCSP-rtTA/TetO-Cre/ LSL-Kras G12D /p53 flox/flox mice. The tumor foci in the lungs were then examined after Kras G12D activation and p53 deletion at week 8 (Fig.   2H ). In the lungs treated with shPuf-A-1 or shPuf-A-2 lentivirus, adenoma formation was reduced by 1.9-and 1.5-fold, respectively, and adenocarcinoma formation was reduced by 4.0-and 2.6-fold, respectively, (Fig. 2I ) compared to controls. These results support an essential role of Puf-A in the development and progression of ADC in the lungs. After transduction with shPuf-A-1 and shPuf-A-2, the expression of Puf-A was markedly reduced compared to control cells (Fig. 3A) . When Puf-A was silenced in p53-proficient cancers, the expression levels of p53 and p21 proteins increased greatly ( Fig. S2a and S2b) compared with control cells. However, there was no apparent change in the expression level of cleaved caspase3 or cleaved poly ADP-ribose polymerase 1 (PARP1) in response to Puf-A silencing in p53-proficient cells (Fig. 3A, left panel) . In contrast,
Puf-A is essential for cancer growth and cell transformation
after Puf-A silencing in the p53-deficient cells cleaved caspase3 and cleaved PARP1 were markedly increased (Fig. 3A , right panel).
The proliferation rates of these cancer cells after silencing Puf-A was obviously reduced (Fig. 3B ). The proportion of p53-proficient cells in the G0/G1 phase after Puf-A silencing increased greatly, whereas the proportion in the S phase was reduced ( 
Puf-A is required for ribosome biogenesis
Increased rRNA transcription in nucleolus is a common feature of cancer cells, which require elevated ribosome biosynthesis to support growth (Baker, Cooke et al., 2017) . We next examined whether Puf-A is involved in rRNA transcription, thereby 4C III, V and VII). These results implied that Puf-A is involved in ribosome assembly.
Puf-A interacts with the 5.8S sequence within pre-rRNA of 90S pre-ribosomes
Western blotting of gradient fractions in polysome profiling assays for nuclear and cytosolic preparations indicated that the 40S, 60S, and 90S pre-ribosomes were found in the nuclear fraction (red curve), while the mature 40S, 60S, and 80S ribosomes and polysomes were in the cytosolic fraction (black curve) in p53 +/+ -and p53
-/--HCT116 cells (Fig. 5A, upper panel) . Notably, protein distributions further showed that Puf-A was found primarily with nuclear 90S pre-ribosomes but not with cytosolic 80S ribosomes; in contrast, S6 and L5 were expressed in both the nucleus and cytoplasm (Fig. 5A, lower panel).
The sub-cellular localization of Puf-A in cells was further examined with specific antibodies in immunostaining. The result showed that HA-tagged Puf-A (red) was colocalized with pre-rRNA (stained with green 5.8S rRNA sequence antibody) primarily in the nucleus, particularly in the nucleolus, but not in the cytoplasm of H1299 cells ( Puf-A belongs to the PUF-family that has RNA-binding activity in variety of spices (Quenault, Lithgow et al., 2011) . To examine whether Puf-A has the capacity to bind to particular pre-rRNA sequences of 90S pre-ribosomes in the nucleolus, purified recombinant human Puf-A protein (rPuf-A) was incubated with total RNA extracts from cells for a pull-down assay. There was a strong RNA band corresponding to a 100~200 nt fragment in the agarose gel analysis (Fig. S3a, left panel) . With the use of 5.8S sequencespecific primers, it was confirmed that this RNA fragment contained 5.8S sequence ( The interactions between Puf-A and the 5.8S sequences in the pre-rRNA were further examined by RNA-protein docking as described in Supplementary Experimental
Procedures using NPDock server (Tuszynska, Magnus et al., 2015) . Through examination of 100 potential models of Puf-A protein in complex with 5.8S rRNA sequences by NPDock, the model which possessed the lowest energy scores was considered as the predicted binding mode and shown in Fig. 5D and S3c. The 5.8S rRNA sequence in the model has 156 nucleotides consisted of four segments, nt 1-37, 37-103, 103-140 and 140-156 (Fig. 5D ). Through analysis of the atomic distances between the atoms of Puf-A and 5.8S rRNA sequences, it was found that three segments of rRNA sequences from nt 37-103, 103-140, and 140-156 intermingled directly with Puf-A protein (with atomic distances shorter than 5 Å). Since the orientation of the segment nt 1-37 is far flung from the Puf-A structure, it is suggested that this segment might not be involved in the binding with Puf-A (Fig. 5D ). On the other hand, human Puf-A had an N-terminal PUF domain S3c ). This finding agrees with the previous report indicating that Puf-A could bind double-stranded nucleic acids (Qiu, McCann et al., 2014) . Here, Puf-A is proposed to specifically interact with the 5.8S sequence within pre-rRNA in the nucleolus.
Since mature 5.8S rRNA resided within 60S ribosome in cytoplasm and the immature 5.8S (the 5.8S sequence within pre-rRNA) was present in pre-ribosomes in the nucleus (Thomson & Tollervey, 2010) , Our finding of co-distribution and co-localization of Puf-A and 5.8S sequence in pre-rRNA ( Fig. 5A and B) further confirm that Puf-A is associated with 90S pre-ribosomes within the nucleolus. Previously, mutation of yeast Puf6 (a homologue of mammalian Puf-A) led to reduction of mature 5.8S, suggesting its involvement in the processing of yeast 7S pre-rRNA (a precursor of 5.8S rRNA) to mature 5.8S rRNA (Qiu et al., 2014) , thus facilitating the assembly of 60S ribosome, which presumably occurred in the cytoplasm (Li, Lee et al., 2009 ). However, in response to Puf-A silencing in various cells, steady state levels of mature 5.8S based on Northern blot analysis were not much altered (Fig. S3d) , suggesting that Puf-A may not participate in the processing for the pre-5.8S rRNA.
Furthermore, silencing of Puf-A impaired the assembly of 90S in the nuclear fraction (Fig. 5E, left panel) , resulting in the reduction of 80S ribosome and polysomes in the cytoplasm (right panel). Therefore, Puf-A interacts with the 5.8S region in the prerRNA, and is involved with the integrity of 90S pre-ribosomes.
Puf-A facilitates the assembly and nuclear export of pre-ribosomes
We further examined the subcellular localization of S6 and L5 protein in response to
Puf-A expression. In MEFs, after transduction with c-Myc alone, the expression of S6 was mainly found in the cytoplasm (Fig. 6A , green, and 6B). By comparison, the expression of L5 was primarily in the nucleolus and also in the cytoplasm (red). When
MEFs were co-transduced with Puf-A and c-Myc, the expression of S6 and L5 was obviously increased and both were co-localized in the cytoplasm (yellow). These results suggest that Puf-A promotes ribosome assembly, thereby facilitating maturation of the 80S ribosome.
In various cancers, both L5 and S6 were co-localized in the cytoplasm (Fig. 6A, 
yellow) but rarely in the nucleolus in control cells, consistent with findings in MEFs with
Puf-A and c-Myc co-expression. After silencing of Puf-A, the expression of S6 and L5 in these cells obviously decreased in the cytoplasm with increase in the nucleolus compared to control cells ( Fig. 6A and 6B ).
These results indicate that silencing of Puf-A leads to accumulation of ribosomal proteins in the nucleus, causing severe ribosome defects in cancer cells.
Puf-A recruits NPM1 in pre-ribosomes and prevents its translocation
To search for Puf-A interacting proteins that mediate the assembly and nuclear export of pre-ribosomes, we performed immunoprecipitation and mass spectrometric analyses which identified NPM1 was as a Puf-A-interacting protein in H1299 cells ( Fig.   S4a and b) . Exogenous HA-tagged Puf-A co-precipitated with flag-tagged NPM1;
endogenous Puf-A was also associated with NPM1 ( Fig. 7A and B) in the nucleolus (Fig.   7C , shLuc). However, upon silencing of Puf-A, the NPM1 was translocated from preribosomes in the nucleoli to the nucleoplasm of these cells (Fig. 7C, shPuf-A-1 ). In addition, silencing of Puf-A in cells did not alter the expression of NPM1 (Fig. 7D) compared to control cells. In cancer cells, NPM1 was found with 40S, 60S and 90S preribosomes ( Fig. 7E I, III and V). However, after transduction with shPuf-A-1, the expression of NPM1 in these pre-ribosomal fractions of nucleolus was decreased significantly, compared to control shLuc cells (Fig. 7E II, IV and VI). These results are consistent with the observation of NPM1 translocation in Fig. 7C .
In MEFs after transduction with c-Myc alone, NPM1 was primarily expressed in non-ribosomal fractions, but not in pre-ribosomal fractions (Fig. 7E, VII) . After cotransduction with Puf-A and c-Myc, there was an increase in the expression of NPM1
with the 40S, 60S and 90S pre-ribosomes in MEFs (Fig. 7E, VIII) . These results suggest that Puf-A recruits NPM1 to pre-ribosomes and prevents its translocation from nucleolus to nucleoplasm, conceivably promoting the assembly of ribosomes.
It was reported that NPM1 participates not only in the regulation of pre-45S rRNA transcription but also in the assembly and nuclear export of pre-ribosomes in various cancers (Maggi, Kuchenruether et al., 2008) . Our results indicated that Puf-A may complex with NPM1 in nucleolus to mediate ribosome biogenesis.
Discussion
As elaborated in graphic illustration (Fig. 8) , we identified Puf-A as a critical factor for 90S pre-ribosome assembly, which regulates early ribosome biogenesis. In transformed and cancer cells, it was found that over-activation of ribosome biogenesis induced by Puf-A is required for Kras G12D /p53 -/--induced tumor progression and cancer growth, including tumors with TP53 mutation. The over-activated ribosome biogenesis is consistent with the concept that cancer cells require extensive protein synthesis, which relies on a constant supply of new ribosomes (Dez & Tollervey, 2004 Furthermore, Puf-A silencing alters the onset of adenomas and significantly prevents the progression to adenocarcinomas in the lungs of Kras G12D /p53 -/-mice.
Silencing of Puf-A in various TP53-mutated cancers and c-Myc/p53
-/--transformed cells increased the expression of apoptotic proteins, such as cleaved caspase3 or cleaved PARP1, culminating in cell apoptosis.
Previously, higher expression levels of Puf-A was reported in human breast cancers with advanced clinical stages (Fan, Lee et al., 2013) . However, the transcriptional regulation of Puf-A in cancer cells and its molecular mechanism underlying cancer promotion were unknown. Here, we have elucidated its key role in ribosome biogenesis, which contributed to tumor progression. In addition, we provided the first evidence that
PUF-A locus harbors the c-Myc and p53 response elements, and the transcription of Puf-
A is positively regulated by c-Myc and negatively regulated by p53. These finding were all summarized in graphical illustration (Fig.8) .
In this study, we also elucidated several distinct features of Puf-A which set it apart from other PUF family proteins, including the differential roles of Puf6, a homolog of Puf-A in yeast, in ribosome biogenesis. In yeast, two assembly factors of 60S ribosome, Pwp1 and Nop12, were reported to participate in the folding of double-stranded structure of 5.8S sequence within pre-rRNA, thereby facilitating its processing (Talkish, Campbell et al., 2014) .
We demonstrated that Puf-A specifically interacts with the nt 37-156 of 5.8S
sequence within pre-rRNA of 90S pre-ribosome, but does not seem to be involved in its processing in the cytoplasm. First, the co-distribution of Puf-A with pre-rRNAs in polysome profiling of nuclear fraction and the co-localization of Puf-A and 5.8S
sequence in pre-rRNA in immunostaining suggest that Puf-A might be associated with 90S pre-ribosomes in nucleolus. Secondly, steady state levels of mature 5.8S based on
Northern blot analysis were not much altered in response to Puf-A silencing in cells.
Thirdly, Puf-A expression seemed to involve in ribosome assembly and its nuclear exports. In other words, Puf-A might be important for proper folding of 5.8S sequence in pre-rRNA, thereby allowing various assembly factors to associate with 90S preribosomes and facilitate ribosome biosynthesis. Thus, our finding regarding how Puf-A interacts with 5.8S sequence is in agreement with the proposal that Puf-A recognizes double-stranded nucleic acids (Qiu et al., 2014) .
The classical PUF proteins (e.g., PUM1 or PUM2), which bind to specific recognition sequences in the 3' untranslated regions (3' UTRs) of mRNAs and control the stability and translation of transcripts, were found in the cytoplasm (Quenault et al., 2011 ). However, Puf-A was unique in its localization in the nucleolus and association with 90S pre-ribosomes in early ribosome biogenesis. In addition, previous report indicated that Puf-A could bind double-stranded nucleic acids without sequence specificity (Qiu et al., 2014) , thus Puf-A may not participate in the processing of specific pre-rRNAs. Thus, Puf-A is distinct from its PUF homologs in its localization in the nucleolus and association with 90S pre-ribosomes.
As a result, Puf-A silencing induced the translocation of NPM1 from the nucleoli to the nucleoplasm, thus causing impairment of the assembly of 40S and 60S ribosomes and leading to defective synthesis of 80S ribosomes and polysomes (Fig.8) . These findings are consistent with the notion that the translocation of NPM1 from nucleoli to the nucleoplasm occurs as a stress signal for ribosome biogenesis, resulting in growth inhibition of cancers (Lindstrom, 2011) .
In contrast, overexpression of Puf-A in MEFs with c-Myc activation enhanced the activity of ribosome biogenesis and dramatically stimulated cell proliferation and transformation. It was found that Puf-A recruited NPM1 within 90S pre-ribosomes and facilitated the assembly of 40S and 60S ribosomes. Our results were consistent with previous studies indicating that NPM1, as a nucleolar-cytoplasmic shuttling protein, promotes the nuclear export of 40S and 60S ribosomes into the cytoplasm to increase the number of 80S ribosomes and polysomes, thus leading to increased cell proliferation (Maggi et al., 2008) . It should be noted that there was no obvious alteration in proliferation rate or phenotypic conversion of normal MEFs in response to Puf-A silencing, suggesting that normal cells with low expression of Puf-A and slow rate of ribosome biogenesis might not be affected by Puf-A silencing.
Finally, our studies reveal that the expression of Puf-A links ribosome biogenesis to cancer progression and further provides a mechanistic explanation for Puf-A regulation of 90S pre-ribosome assembly. The anti-cancer effects of targeting Puf-A were observed in many cancers, including lung, colon, and breast cancers. Thus, the study provides a strategy to treat a variety of cancers.
Materials and Methods
Experimental procedures are detailed in the Supplementary Information. 
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C.
Immuno-histochemical analysis of p53 expression in tissue sections of lung cancer.
The intensity of p53 staining was divided into two groups: "p53 mut" refers to tumor cells with strong nuclear p53 staining and "p53 WT" refers to those with weak or no Table S2 ).
H. The experimental design after in vivo intranasal administration of lentivirus to silence
Puf-A expression in the lung tissues of CCSP-rtTA/TetO-Cre /LSL-Kras G12D /p53 flox/flox mice after simultaneous Kras G12D activation and p53 deletion.
I.
The decrease in the number of tumor foci in mice after intranasal administration of, shPuf-A-1 counted in the tissue sections. Mean ± SEM values are shown for control shLacZ (n = 13), shPuf-A-1 (n = 11), and shPuf-A-2 (n = 6). * and *** refer, respectively, to p < 0.05 and p < 0.001 (one-way ANOVA). 
